HER2-Targeted Antibody Treatment for Ovarian Cancer Future Opportunities
Received Date: Jun 21, 2016 / Accepted Date: Jun 23, 2016 / Published Date: Jun 27, 2016
There are an estimated 240,000 new cases of ovarian cancer diagnosed worldwide each year. Due to late presentation, in many parts of the world it remains the most lethal gynecological cancer. In 2004, a new model description of this disease was proposed that combined both histopathological and molecular features and which classified epithelial ovarian cancers into two broad categories designated Type I and Type II tumors.
Keywords: Ovarian cancer; Chemotheraphy; Biomarkers
Citation: Langdon SP, Andrew H Sims (2016) HER2-Targeted Antibody Treatment for Ovarian Cancer – Future Opportunities. J Mol Pharm Org Process Res 4: e125. Doi: 10.4172/2329-9053.1000e125
Copyright: ©2016 Langdon SP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
- Total views: 9435
- [From(publication date): 6-2016 - May 28, 2018]
- Breakdown by view type
- HTML page views: 9279
- PDF downloads: 156